Categories Health Care, Interviews, LATEST

Continued focus on core B2B segment drives new business: Trxade CEO Suren Ajjarapu

In a conversation with AlphaStreet, Trxade's CEO Suren Ajjarapu speaks about the company’s recent financial performance

Trxade Health Inc. (NASDAQ: MEDS), a leading online drug procurement marketplace, is on a mission to provide independent pharmacies a platform to operate efficiently by digitalizing the retail pharmacy experience. Over the years, the company has constantly expanded its customer network and developed the core business, while also pursuing strategic partnerships.

The company operates through the business segments of, Community Specialty Pharmacy, and Trxade Prime. Speaking to AlphaStreet, after reporting impressive results for the fourth quarter of 2022, Trxade’s chief executive officer Suren Ajjarapu provided insights into the company’s financial performance in fiscal 2022.

Suren Ajjarapu

Commenting on the management’s decision to sell 100% of outstanding membership interest in the Community Specialty Pharmacy business, Suren said, “Our core business is B2B, focusing on that vs Community Specialty Pharmacy really drives new business and we can reallocate those resources to B2B. I understand you may see a revenue drop in the first two quarters but margin will be high as B2B is tech business vs Community Specialty Pharmacy has the ‘cost of goods sold’ driving margins down.

He attributed the decline in expenses in recent quarters to a cost-cutting strategy and believes that the initiative would eventually translate into profitability in a couple of quarters. When it comes to driving long-term growth, integration with POS systems would be a key focus this year, besides partnerships, according to Suren.

On being asked how the business evolved since last year, Suren said integration is the one major change the company is witnessing from 12 months ago. According to him, the strong margin growth in fiscal 2022 was the result of the strategy to move back to core tech platform sales, which has 78% gross margins.

It is worth noting that total gross profit grew 15% annually in fiscal 2022, aided by a 16% increase in revenues to $11.4 million. Double-digit increase in the Trxade and Trxade Prime segments more than offset weakness in the Community Specialty Pharmacy division.

Trxade FY 2022 earnings infographic

The number of registered users on the Trxade Platform increased by 8%, taking the total to more than 14,400. The company ended the year with total cash of $1.13 million. Full-year net loss narrowed to $3.47 million or $0.41 per share from $5.32 million or $0.65 per share in the prior year.

Trxade’s disruptive business model is focused on opening channels of distribution to help pharmacies and patients purchase healthcare products at reasonable prices. The company has been successful in bringing price transparency to the pharmaceutical marketplace and providing significant savings to customers. The long-term goal is to make healthcare accessible and affordable to all patients.

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Ulta Beauty (ULTA) Earnings: 1Q23 Key Numbers

Ulta Beauty, Inc. (NASDAQ: ULTA) reported net sales of $2.6 billion for the first quarter of 2023, up 12.3% from the same period a year ago. Comparable sales grew 9.3%.

Costco (COST) Q3 2023 earnings drop on weak sales growth

Costco Wholesale Corporation (NASDAQ: COST) on Thursday reported a 2% increase in third-quarter 2023 revenues. However, the warehouse behemoth's earnings declined. Third-quarter revenue increased 1.9% to $53.6 billion from $52.6 billion

Key takeaways from Dollar Tree’s (DLTR) Q1 2023 earnings report

Shares of Dollar Tree, Inc. (NASDAQ: DLTR) were down 9% on Thursday after the company delivered mixed results for the first quarter of 2023. The discount retailer missed expectations on

Add Comment
Viewing Highlight